DR. REDDY S LABORATORIES

Dr. Reddy's Laboratories Limited reported a revenue decline of 5.6% for Q1 FY27, with consolidated revenues at ₹8,071 crores (US$853 million). The decline was attributed to lower lenalidomide revenues and a provision of ₹240 crores related to semaglutide API challenges. However, the underlying base business showed healthy double-digit growth across key geographies, including North America. The EBITDA margin was reported at 12.5%, impacted by the semaglutide-related issues and higher costs due to the Middle East conflict. Management highlighted strong performance in the India and Emerging Markets segments, with India achieving 17% year-on-year growth. The company plans to resume semaglutide supplies by November and remains focused on strategic priorities in peptides, biosimilars, and consumer health. The earnings call included discussions on regulatory updates, product launches, and ongoing productivity initiatives.

The document presented both challenges and positive growth indicators across various segments.